These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 16329138

  • 1. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
    Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ.
    Cancer; 2006 Jan 01; 106(1):58-62. PubMed ID: 16329138
    [Abstract] [Full Text] [Related]

  • 2. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
    Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.
    Cancer; 2007 Aug 01; 110(3):556-63. PubMed ID: 17577218
    [Abstract] [Full Text] [Related]

  • 3. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M, Tangen CM, Lara PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED, Southwest Oncology Group.
    J Clin Oncol; 2005 Dec 01; 23(34):8724-9. PubMed ID: 16314632
    [Abstract] [Full Text] [Related]

  • 4. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK.
    J Clin Oncol; 2005 Mar 01; 23(7):1439-46. PubMed ID: 15735119
    [Abstract] [Full Text] [Related]

  • 5. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.
    Cancer; 2011 Jun 01; 117(11):2419-25. PubMed ID: 24048789
    [Abstract] [Full Text] [Related]

  • 6. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.
    BJU Int; 2008 Feb 01; 101(3):308-12. PubMed ID: 18184327
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S, Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group.
    Lancet Oncol; 2007 Nov 01; 8(11):994-1000. PubMed ID: 17942366
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Michels J, Montemurro T, Murray N, Kollmannsberger C, Nguyen Chi K.
    Cancer; 2006 Mar 01; 106(5):1041-6. PubMed ID: 16456811
    [Abstract] [Full Text] [Related]

  • 14. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T, Klatte T, Yap R, Kalinski T, Röpke A, Filleur S, Allhoff EP.
    BJU Int; 2006 Sep 01; 98(3):580-5. PubMed ID: 16925757
    [Abstract] [Full Text] [Related]

  • 15. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T, Reiher F, Lindenmeir T, Klatte T, Rau O, Burandt J, Filleur S, Allhoff EP.
    Onkologie; 2005 Nov 01; 28(11):573-8. PubMed ID: 16249643
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.
    Clin Cancer Res; 2005 Jan 01; 11(1):284-9. PubMed ID: 15671557
    [Abstract] [Full Text] [Related]

  • 17. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J.
    J Clin Oncol; 2008 Nov 10; 26(32):5261-8. PubMed ID: 18794543
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.
    Cancer J; 2007 Nov 10; 13(2):125-9. PubMed ID: 17476141
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.